Novartis Contracts with Cryoport to Support Novartis Cell Therapies

Article

Applied Clinical Trials

Novartis has signed an aggreement contracting Cryoport-provider of logistics solutions for biopharmaceutical, IVF, and animal health organizations globally-over an initial three-year tern for cryogenic logistics support of CTL019/CD19 CAR-T cell therapy.

Read the full release here.

 

 

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.